CYP1A1 Ile462Val polymorphism contributes to colorectal cancer risk: a meta-analysis.
OBJECTIVE
To study the relation between CYP1A1 Ile462Val polymorphism and colorectal cancer risk by meta-analysis.


METHODS
A meta-analysis was performed to investigate the relation between CYP1A1 Ile462Val polymorphism and colorectal cancer risk by reviewing the related studies until September 2010. Data were extracted and analyzed. Crude odds ratio (OR) with 95% confidence interval (CI) was used to assess the strength of relation between CYP1A1 Ile462Val polymorphism and colorectal cancer risk.


RESULTS
Thirteen published case-control studies including 5336 cases and 6226 controls were acquired. The pooled OR with 95% CI indicated that CYP1A1 Ile462Val polymorphism was significantly related with colorectal cancer risk (Val/Val vs Ile/Ile: OR = 1.47, 95% CI: 1.16-1.86, P = 0.002; dominant model: OR = 1.33, 95% CI: 1.01-1.75, P = 0.04; recessive model: OR = 1.49, 95% CI: 1.18-1.88, P = 0.0009). Subgroup ethnicity analysis showed that CYP1A1 Ile462Val polymorphism was also significantly related with colorectal cancer risk in Europeans (Ile/Val vs Ile/Ile: OR = 1.22, 95% CI: 1.05-1.42, P = 0.008; dominant model: OR = 1.24, 95% CI: 1.07-1.43, P = 0.004) and Asians (Val/Val vs Ile/Ile: OR = 1.40, 95% CI: 1.07-1.82, P = 0.01; recessive model: OR = 1.46, 95% CI: 1.12-1.89, P = 0.005).


CONCLUSIONS
CYP1A1 Ile462Val may be an increased risk factor for colorectal cancer.
Department of Pathology, Affiliated No. 4 Hospital of Soochow University, Wuxi 214062, Jiangsu Province, China.
Jian-Qiang
JQ
Jin
Yuan-Yuan
YY
Hu
Yu-Ming
YM
Niu
Gong-Li
GL
Yang
Yu-Yu
YY
Wu
Wei-Dong
WD
Leng
Ling-Yun
LY
Xia
D016022:Case-Control Studies; D015179:Colorectal Neoplasms / Q000235:genetics*; D019363:Cytochrome P-450 CYP1A1 / Q000235:genetics*; D005260:Female; D005838:Genotype; D006801:Humans; D007532:Isoleucine / Q000235:genetics*; D008297:Male; D008957:Models, Genetic; D016017:Odds Ratio; D011110:Polymorphism, Genetic; D012306:Risk; D012307:Risk Factors; D014633:Valine / Q000235:genetics*
D007532:Isoleucine; D019363:Cytochrome P-450 CYP1A1; D014633:Valine
Am J Epidemiol. 2002 Aug 15;156(4):300-10
12181099
J Nutr. 2005 Feb;135(2):179-86
15671210
Breast Cancer Res Treat. 2010 Jul;122(2):459-69
20035380
Carcinogenesis. 2002 Nov;23(11):1839-49
12419832
Cancer Epidemiol Biomarkers Prev. 2009 Oct;18(10):2745-50
19755657
Am J Epidemiol. 2004 Nov 1;160(9):842-52
15496536
BMJ. 1997 Sep 13;315(7109):629-34
9310563
Anticancer Res. 2007 Jul-Aug;27(4C):2931-7
17695473
CA Cancer J Clin. 2005 Mar-Apr;55(2):74-108
15761078
Int J Cancer. 2006 Nov 1;119(9):2155-64
16823842
Mutat Res. 1991 Apr;247(2):267-81
2011144
J Biomed Sci. 2007 Mar;14(2):183-93
17191090
Gastroenterology. 2010 Sep;139(3):788-96, 796.e1-6
20638935
Asian Pac J Cancer Prev. 2007 Jul-Sep;8(3):438-44
18159984
Int J Biol Markers. 2008 Jan-Mar;23(1):18-23
18409146
J Natl Cancer Inst. 1959 Apr;22(4):719-48
13655060
Control Clin Trials. 1986 Sep;7(3):177-88
3802833
Ann Intern Med. 1997 Nov 1;127(9):820-6
9382404
Cancer Epidemiol Biomarkers Prev. 2000 Aug;9(8):855-6
10952105
Nat Rev Cancer. 2006 Dec;6(12):947-60
17128211
Cancer Epidemiol Biomarkers Prev. 2008 Feb;17(2):405-13
18268125
Pharmacogenet Genomics. 2005 Aug;15(8):535-46
16006997
Cancer Res. 1994 Jul 15;54(14):3692-5
7913406
Scand J Gastroenterol. 2009;44(8):952-9
19452301
BMC Cancer. 2010 Jun 10;10:274
20534171
Nat Genet. 2008 May;40(5):623-30
18372905
Anticancer Res. 2000 Jan-Feb;20(1B):519-22
10769717
Biochim Biophys Acta. 2003 Feb 17;1619(3):223-34
12573481
Urol J. 2009 Spring;6(2):78-86
19472123
Arch Intern Med. 2006 Mar 27;166(6):629-34
16567601
Clin Pharmacokinet. 1994 Jan;26(1):59-70
8137598
Acta Oncol. 2010 Jun;49(5):532-44
20491522
Arch Med Res. 2009 Apr;40(3):169-79
19427967